Search Results - "Houghton, Baerin"

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

“…Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with…”
Get full text

Intravesical chemotherapy plus bacille Calmette‐Guérin in non‐muscle invasive bladder cancer: a systematic review with meta‐analysis by Houghton, Baerin B., Chalasani, Venu, Hayne, Dickon, Grimison, Peter, Brown, Christopher S. B., Patel, Manish I., Davis, Ian D., Stockler, Martin R.

“…What's known on the subject? and What does the study add? Non‐muscle‐invasive bladder cancer has a significant recurrence and progression rate despite…”
Get full text

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials by Borghaei, Hossein, Langer, Corey J., Paz‐Ares, Luis, Rodríguez‐Abreu, Delvys, Halmos, Balazs, Garassino, Marina C., Houghton, Baerin, Kurata, Takayasu, Cheng, Ying, Lin, Jianxin, Pietanza, M. Catherine, Piperdi, Bilal, Gadgeel, Shirish M.

“…Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated improved clinical outcomes over chemotherapy alone in patients with previously…”
Get full text

Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799 by Reck, Martin, Lee, Ki Hyeong, Frost, Nikolaj, Breder, Valeriy Vladimirovich, Kowalski, Dariusz M., Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufiia, Liu, Hong, Novinskiy, Vladimir, Dettman, E.J., Kobie, Julie, Jabbour, Salma K.

“…8057 Background: The nonrandomized phase 2 KEYNOTE-799 study (NCT03631784) of pembro + cCRT in previously untreated unresectable, locally advanced, stage III…”
Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma by Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

“…Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with…”
Get full text

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC by Reck, Martin, Lee, Ki Hyeong, Frost, Nicolaj, Breder, Valeriy Vladimirovich, Kowalski, Dariusz, Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufiia, Komiya, Takefumi, Sanford, Amy, Liu, Hong, Song, Andrew J., Keller, Steven M., Jabbour, Salma K.

“…8508 Background: Primary analysis (database cutoff, Oct 28, 2020) of the global KEYNOTE-799 study (NCT03631784) in patients (pts) with unresectable, locally…”
Get full text

Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867 by Jabbour, Salma K., Houghton, Baerin, Robinson, Andrew George, Quantin, Xavier, Wehler, Thomas, Kowalski, Dariusz, Ahn, Myung-Ju, Erman, Mustafa, Giaccone, Giuseppe, Borghaei, Hossein, McLean, Jessica, Xu, Yan, Souza, Fabricio, Pall, Georg

“…TPS8597 Background: Anti–PD-(L)1-directed therapy following radiotherapy or following concurrent chemoradiation is associated with significantly longer PFS and…”
Get full text

Abstract CT288: Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with inoperable stage I/IIA non-small-cell lung cancer (NSCLC): KEYNOTE-867 by Jabbour, Salma K., Houghton, Baerin, Robinson, Andrew G., Quantin, Xavier, Wehler, Thomas, Kowalski, Dariusz, Ahn, Myung-Ju, Erman, Mustafa, Giaccone, Giuseppe, Borghaei, Hossein, McLean, Jessica, Zhang, Jin, Souza, Fabricio, Decker, Roy

“…Abstract Background: Anti-PD-(L)1-directed therapy following radiotherapy or following concurrent chemoradiation is associated with significantly longer PFS…”
Get full text

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799 by Jabbour, Salma K., Lee, Ki Hyeong, Frost, Nicolaj, Kowalski, Dariusz, Breder, Valeriy Vladimirovich, Pollock, Theodore, Reguart, Noemi, Houghton, Baerin, Quantin, Xavier, Keller, Steven M., Liu, Hong, Piperdi, Bilal, Reck, Martin

“…Abstract only 9008 Background: KEYNOTE-799 (NCT03631784) evaluates pembro plus concurrent chemoradiation therapy (CCRT) in pts with unresectable, locally…”
Get full text

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC by Jabbour, Salma K., Lee, Ki Hyeong, Frost, Nicolaj, Breder, Valeriy Vladimirovich, Kowalski, Dariusz M., Alawin, Issam Abdelkarim, Levchenko, Evgeny, Reguart, Noemi, Martinez-Marti, Alex, Houghton, Baerin, Paoli, Jean-Baptiste, Safina, Sufia, Park, Keunchil, Komiya, Takefumi, Sanford, Amy, Boolell, Vishal, Liu, Hong, Samkari, Ayman, Keller, Steven M., Reck, Martin

“…Abstract only 8512 Background: KEYNOTE-799 (NCT03631784) is an ongoing study of the anti‒PD-1 antibody pembrolizumab (pembro) plus concurrent chemoradiation…”
Get full text

Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC) by Hughes, Brett, Dean, Andrew, Markman, Ben, Dreisbach, Luke, Provencio, Mariano, Ciuffreda, Libero, Dear, Rachel, Graze, Peter, Nadal, Alforia, Houghton, Baerin, Moran, Teresa, Roberts, Rachel, Dy, Grace, Alvaro, Taus, Martinez Marti, Alex, Brachmann, Rainer, Stagg, Robert, Govindan, Ramaswamy

“…Abstract Introduction: Delta-like ligand 4 (DLL4) is a ligand that activates the Notch pathway, which is important for cancer stem cell (CSC) survival…”
Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Graham Cohen, Bernardo Rapoport, Sze W. Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P. Brown, Robert M. Zielinski, Eva Muñoz Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

Get full text

Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer by Grimison, Peter, Houghton, Baerin, Chatfield, Mark, Toner, Guy C., Davis, Ian D., Martin, Jarad, Hovey, Elizabeth, Stockler, Martin R.

“…Objective To determine the patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer during 2010…”
Get full text

Patterns of management and surveillance imaging amongst medical oncologists in A ustralia for stage I testicular cancer by Grimison, Peter, Houghton, Baerin, Chatfield, Mark, Toner, Guy C., Davis, Ian D., Martin, Jarad, Hovey, Elizabeth, Stockler, Martin R.

“…Objective To determine the patterns of management and surveillance imaging amongst medical oncologists in A ustralia for stage I testicular cancer during 2010…”
Get full text

Intravesical chemotherapy plus bacille C almette‐ G uérin in non‐muscle invasive bladder cancer: a systematic review with meta‐analysis by Houghton, Baerin B., Chalasani, Venu, Hayne, Dickon, Grimison, Peter, Brown, Christopher S. B., Patel, Manish I., Davis, Ian D., Stockler, Martin R.

“…What's known on the subject? and What does the study add? Non‐muscle‐invasive bladder cancer has a significant recurrence and progression rate despite…”
Get full text

Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis : Urological Oncology by HOUGHTON, Baerin B, CHALASANI, Venu, HAYNE, Dickon, GRIMISON, Peter, BROWN, Christopher S. B, PATEL, Manish I, DAVIS, Ian D, STOCKLER, Martin R

Get full text